Fitusiran
- Generic Name
- Fitusiran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1499251-18-1
- Unique Ingredient Identifier
- SV9W47ZLE1
- Background
Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT05662319
- Locations
- 🇺🇸
Center for Inherited Blood Disorders (CIBD) Site Number : 8400012, Orange, California, United States
🇺🇸University of California San Diego Site Number : 8400011, San Diego, California, United States
🇺🇸University of Minnesota Site Number : 8400016, Minneapolis, Minnesota, United States
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 32
- Registration Number
- NCT03974113
- Locations
- 🇺🇸
Hackensack University Medical Center Site Number : 8400008, Hackensack, New Jersey, United States
🇺🇸University Hospitals of Cleveland Site Number : 8400007, Cleveland, Ohio, United States
🇮🇳Investigational Site Number : 3560006, Bangalore, India
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 281
- Registration Number
- NCT03754790
- Locations
- 🇺🇸
Children's Hospital Los Angeles Site Number : 8400019, Los Angeles, California, United States
🇺🇸Rush University Medical Center -1725 W Harrison St Site Number : 8400001, Chicago, Illinois, United States
🇺🇸~Massachusetts General Hospital Site Number : 8400011, Boston, Massachusetts, United States
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 80
- Registration Number
- NCT03549871
- Locations
- 🇺🇦
Investigational Site Number 8003, Kyiv, Ukraine
🇲🇾Investigational Site Number 6004, Ampang, Malaysia
🇹🇷Investigational Site Number 9002, Adana, Turkey
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT03417245
- Locations
- 🇺🇸
Investigational Site Number 119, New Orleans, Louisiana, United States
🇦🇺Investigational Site Number 6101, Camperdown, Australia
🇨🇳Investigational Site Number 8602, Guangzhou, China
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT03417102
- Locations
- 🇨🇳
Investigational Site Number 8804, Taiwan, Taiwan
🇹🇷Investigational Site Number 9002, Adana, Turkey
🇺🇦Investigational Site Number 8003, Kyiv, Ukraine
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 51
- Registration Number
- NCT02035605
- Locations
- 🇬🇧
Clinical Trial Site, Truro, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.